The antigen presenting cells instruct plasma cell differentiation

Wei Xu1 * and Jacques Banchereau2

1 Pharma Research and Early Development, F Hoffmann-La Roche Ltd., Roche Glycart AG, Schlieren, Switzerland
2 The Jackson Laboratory, Institute for Genomic Medicine, Farmington, CT, USA

INTRODUCTION

B cell activation is initiated following engagement of the B cell receptor (BCR) by a specific antigen in either a T-cell-dependent (TD) or T-cell-independent (TI) manner (1). Most long-lived plasma cells (PCs) in the bone marrow are derived from TD responses involving germinal center reactions followed by niches favoring long-term survival. As it usually takes several days for the cognate T cells to help, a prompt TI response provides the first wave of humoral protection by generating short-lived PCs in the extrafollicular foci of the peripheral lymphoid organs such as lymph nodes, spleen, Peyer’s patches, and tonsils (2). Indeed, some TI challenges could also induce long-lived antibody responses (3–5).

Professional antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages, present antigens to T cells to initiate adaptive immunity by sequentially delivering signal 1 (antigen), signal 2 (co-stimulation), and signal 3 (polarizing signals mediated by soluble or membrane-bound factors) (6). They can, by similar means, initiate and guide B cell differentiation toward PCs in a TI manner. Precisely, DCs and macrophages efficiently take up large size antigens (such as particulates, immune complexes, and virus that travel through the subcapsular sinus), and present them to naïve B cells in the periphery lymphoid organs (2). Recent advances have revealed that APCs deliver not only “signal 1” (the antigen), but also “signal 2” to directly instruct the differentiation process of PCs in a T-cell-independent manner. Herein, the different signals provided by these APC subsets to direct B cell proliferation, survival, class switching, and terminal differentiation are discussed. We furthermore propose that the next generation of vaccines for boosting antibody response could be designed by targeting APCs.

Keywords: plasma cells, antigen presenting cells, macrophages, dendritic cells, B cells

DC SUBSETS INSTRUCT B CELL DIFFERENTIATION

Back in the 1990s, following the early milestone discovery of DCs in mouse (7) and human (8), DCs have been recognized for their capacity of priming naïve B cells in human in vitro settings (9–11). In the presence of CD40 signaling, naïve B cells undergo class switching toward IgA1 and IgA2 isotype by DCs, and class switching (11). These early works using human monocyte-derived DCs provided the first evidence that in addition to their capacity to activate naïve T cells in the extrafollicular areas of secondary lymphoid organs, DCs may directly modulate B cell growth and differentiation. Similarly, mouse splenic DCs were able to interact with naïve B cells and induce TI class switching in vitro and in vivo (12).

Dendritic cells directly induce TI Ab class switching through the upregulation of B lymphocyte stimulator protein (BLyS, also known as BAFF), and a proliferation-inducing ligand (APRIL) (13). BAFF binds to three different receptors, namely transmembrane activator and calcium modulator and cyclophylin ligand interactor (TACI), B cell maturation antigen (BCMA), and BAFF receptor (BAFF-R) (14–18). On the other hand, APRIL binds to BCMA with high affinity and to TACI with low affinity, but not to BAFF-R (19, 20). Through engagement with its receptors, BAFF activates a CD40-like pathway that enhances B cell survival via upregulation of NF-κB and Bcl-2 (21). APRIL appears to induce AID expression in B cells through NF-κB-mediated HoxC4 induction (22). The importance of BAFF and APRIL has been documented in animal models where mice deficient for BAFF or APRIL showed a defect in IgA production (23, 24). Interestingly, B cells exposed to BAFF and APRIL do not secrete IgG and IgA.
monocyte-derived DCs, appear to be the ones that preferentially prime B cells for humoral response while poorly triggering CD8+ T cell immunity (31), owing to their capacity to polarize follicular T help cells (Tfh) via DC-derived molecular such as IL-6 (32–34). Plasmacytoid DCs, the professional type-1 interferon (IFN)-producing cells, promote the differentiation of CD40-stimulated B cells into non-antibody-secreting plasmablasts via IFN-αβ. They sequentially differentiate into antibody-secreting PCs upon additional IL-6 secreted by pDCs (35). Both B cells and pDCs express TLR9. IFN-α production by CpG ligation of the TLR9 on pDCs also generate IgM-producing PCs from both naive and memory B cells in a TI manner, under the help of other pDC-derived factors such as IL-6, TNF-α, and IL-10 (36). TLR9 ligation of pDCs enhances their CD70 expression to trigger CD27 signaling for B cell survival and differentiation, particularly on memory cells (37). Type-1 IFN can also contribute to PC differentiation indirectly via the upregulation of BAFF and APRIL on myeloid DCs to promote B cell survival, proliferation, and class switching (38), or via promoting Tfh differentiation through myeloid DCs (39). In autoimmune disorders such as systemic lupus erythematosus (SLE), pDCs could be the driver favoring persistence of autoreactive PCs, giving the abnormal signature of type-1 IFN and autologous DNA and DNA-binding proteins (40–42). Indeed, activated pDCs trigger anti-snRNP B cells for enhanced proliferation and antibody production in the mouse (43).

How do B cells acquire antigens from DCs? DCs are found not only in the T cell areas of lymphoid organs where they are ready to prime T cells, but are also interacting with B cells in the follicular areas (44), the red pulp (45), and the marginal zones (46). DCs have a specialized capacity for the retention of antigens (44), enabling delivery of microbes from the intestinal lumen to secondary lymphoid structures (47, 48). Intravital two-photon imaging has revealed that upon lymph node entry, B cells physically survey local antigen-carrying DCs (49). DCs use different receptors to sample antigens that are directed to the degradative compartment for peptide and MHC loading. Interestingly, these antigens were trapped in a native form, and recycled to the cell surfaces for the activation of B cells. This strategy for sorting and recycling native antigens through a non-degradative compartment is also used by follicular DCs to access B cells (51). Another inhibitory receptor, dendritic cell immunoreceptor (DCIR), holds the similar property as FcγRIIB for native antigen recycling utilized by marginal zone DCs to initiate B cell activation in a TD manner (52). It has been reported that even in the degradative late endosome, antigens can be released unprocessed by DCs (53). Thus DCs are equipped with an array of machinery to efficiently retain native antigens to BCR engagement on naive B cells in a TI or TD manner.

**MACROPHAGE SUBSETS INSTRUCT B CELL DIFFERENTIATION**

Due to the nature of lymphoid structure, it has been conceived for a long time that lymph-born antigens must pass through a zone of macrophages that are beneath the subcapsular sinus en route to secondary lymphoid structures.
to reach the follicular B cells (54–56). Macrophages are known to retain antigens for up to 72 h after being exposed to them (57). The very first evidence that macrophages process large size antigens (immune complexes, particulates, and viruses) to present to follicular B cells were found by three impendent groups (58–61). The subcapsular sinus macrophages possibly use CD169 or MAC1 (macrophage receptor 1) to retain antigens on their surface, and consequently B cells acquire antigens from them cumulatively and became the main antigen carriers inside the follicle before polarizing to the B cell-T cell border (58, 59). These studies clearly defined the essential roles of macrophage subsets in the initiation of B cell activation toward lymph-born antigens through dual actions: (1) as innate “flypaper” by preventing the systemic spread of pathogen; (2) as “gatekeepers” at the lymph-tissue interface that facilitate the recognition antigens by B cells and initiate humoral immune responses.

Macrophages residing in the marginal zone have the similar capacity to capture antigen in the spleen (62). Marginal zone macrophages (MZM) express a distinct set of receptors MARCO (macrophage receptor with a collagenous structure) and/or SIGNR1 (a mouse homolog of DC-SIGN), and are therefore different from metallophilic macrophages that express MOMA-1. The first study performed by Ravetch and his colleagues showed that MARCO⁺ MZM migrate to the red pulp of the spleen and transfer the intact antigens to B cells (63). It seems that SIGNR1 is important for the MZM-mediated B cell response, as MZM that lack expression of SIGNR1 failed to capture the model antigen Ficol (64), and mice deficient for SIGNR1 failed to mount a humoral response following infection with Streptococcus pneumoniae (65).

In humans, the evidence for an exclusive role of macrophages in the induction of humoral response remains scarce. We recently identified that resident tissue macrophages in human tonsils reside closely to the terminally differentiated CD138⁺ PCs. We went on to unravel that macrophage-derived IP-10 participates in PC development (proliferation, class switching, and terminal differentiation) in the context of an amplification loop where B cell-derived IL-6 induces macrophages to secrete IP-10, which further boosts the B cell autocrine secretion of IL-6 leading to PC differentiation (Figure 2) (66). This is the first evidence that a chemokine plays direct role in cell differentiation. In addition, macrophages use VCAM-1 to tether B cells for the delivery of signals (66), supporting the earlier findings that VCAM-1 receptor-ligand interaction promotes membrane-bound antigen recognition and formation of an immune synapse (67).

Like DCs, macrophages promote TI class switching recombination by releasing the essential factors BAFF and APRIL (68–70). Macrophage-derived BAFF and APRIL expression can be enhanced by T cell signals such as IFN-γ and CD40L (68). B cell proliferation and antibody secretion following by BAFF and APRIL stimulation also requires co-stimulatory signals such as IL-6, IL-10, and TGF-β (13, 68, 70). This also implies that there are redundant signaling pathways involved in PC differentiation. For example, in rodents, subcapsular macrophages activate extracellular B cells indirectly through presenting CD1d-restricted glycolipid antigens to iNKT cells. PCs homing to the bone marrow require survival niches for long-term residence, and macrophages and their precursors provide such help through APRIL and IL-6 (71–73).

TARGETING APCs FOR A BETTER VACCINE FOR HUMORAL IMMUNITY

Accumulating evidence suggest that APC subsets including DCs and macrophages not only provide “signal 1” for BCR engagement on B cells (74, 75), but further participate in a later stage of cell proliferation and differentiation by providing an additional “signal 2 or 3” such as membrane-bound or soluble factors. While interruption of this pathway might represent an efficient strategy to treat autoimmune diseases, enhancing APC-B cell crosstalk, for example by targeting Ag directly to APCs, may lead to enhanced vaccine-induced Ab responses (Figure 3).

Lessons of early pioneering studies in vivo targeting DCs through coupling the antigens to a specific receptors such as DEC-205, or DCIR for T cell immunity have paved a solid path toward understanding the efficiency of antigen degradation, and (cross-) presentation (76–78). Indeed, targeting antigens to DC through DCIR (79, 80), DC-SIGN (81), dendin-1 (82), CLEC9A (83), and Langerin (84) generated both humoral and cellular responses. Interestingly, in the absence of adjuvant, targeting antigens to CLEC9A on DCs results in strong antibody response, which is linked to the generation of Tfh cells (85), but no CD8⁺ T cell immunity despite of the antigen capture and cross-presentation by targeted CD8α⁺ DCs (83). However, an addition of adjuvant, e.g., poly I:C, skewed a robust CD4⁺ and CD8⁺ T cell response (83, 86). Thus, particular DC subsets, antibodies specific for surface receptors, and appropriate adjuvants, combine to define the sequential immune response by DC targeting (Table 1) (87).

The strategy of a targeted DC vaccine with an antigen to boost antibody response has met the proof of concept. In two of the studies, targeting DCs through CD11c (N418) showed robust humoral immunity resulting from germinal center formation (88, 89), though mechanistic details about antigen internalization and transfer and the factors involved in PC generation by DCs were lacking. Likely, two principles must be followed to design a better vaccine to boost Ab response by targeting DCs in humans;
FIGURE 3 | Targeting APC subsets for a better vaccine for humoral immunity. A fusion protein of Ab (recognizing a particular receptor on APC subset) and Ag complex facilitates Ag uptake by targeted APC subset, which processes Ag to B cells to trigger PC differentiation. An adjuvant (for example IP-10) could be linked to the fusion protein to provide additional signals for PC generation and maintenance.

Table 1 | Strategy to design a APC-targeted vaccine.

| Selection of APCs | Selection of targeting receptors | Selection of adjuvant |
|-------------------|----------------------------------|-----------------------|
| DCs               | FcγRIIB                          | IP-10                 |
|                   | DCIR                             | IL-6                  |
|                   | DC-SIGN                          | APRIL                 |
|                   | Dectin-1                         | BAFF                  |
|                   | CLEC9A                           |                       |
|                   | Langerin                         |                       |
|                   | CD11c                            |                       |
| Macrophages       | CD163                            |                       |
|                   | FcγRIIB                          |                       |

To design the appropriate targeted vaccine, three criteria need to be considered: (1) Select the appropriate DC or macrophage subsets as the targeting APCs; (2) select appropriate receptor to target, preferentially those receptors with capacity of Ag recycling and retention, such as DCIR or FcγRIIB; (3) Select appropriate adjuvant to provide additional help for PC differentiation.

CONCLUDING REMARKS

The past decade has witnessed the important roles of DCs and macrophages in educating B cell activation, proliferation, and differentiation toward PCs. These APC subsets residing at distinct organs might be equipped different sentinels to initiate the prompt humoral response. For example, the subcapsular sinus macrophages, which form a thick lining beneath the capsular in the lymph node, represent the prime APCs to deliver combined signals to naïve B cells for priming. As compared to DC-targeted vaccines for T cell immunity that are applied for more than a decade (91), we are just beginning to design APC-targeted vaccines aiming to enhance antibody responses. As such, various studies have helped our understandings that the interplay of several distinct factors needs to be considered (1) selection of APC subsets as the target cells; (2) selection of appropriate surface receptors as the antibody target; (3) selection of adjuvant.
REFERENCES

1. Fagarasan S, Honjo TT. Independent immune response: new aspects of B cell biology. Science (2000) 290(5489):89–92. doi:10.1126/science.290.5489.89

2. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol (2009) 9(1):15–27. doi:10.1038/nri2454

3. Alugupalli KR, Leong JM, Woodland RT, Muramatsu M, Honjo T, Gerstein RM. Bb lymphocytes confer T cell-independent long-lasting immunity. Immunity (2004) 21(3):379–80. doi:10.1016/j.immuni.2004.06.019

4. Oblozinsky P, Zuzuev MG, T independent type II immune responses generate memory B cells. J Exp Med (2006) 203(2):305–10. doi:10.1084/jem.20052036

5. Hsu MC, Toellner KM, Vinuesa GC, Maclennan IC. B cell clones that sustain long-term plasmablast growth in T-independent extracellular antibody responses. Proc Natl Acad Sci U S A (2006) 103(15):5905–10. doi:10.1073/pnas.0601502103

6. Kapensen ML. Dendritic cell-control of pathogen-driven T-cell polarization. Nat Rev Immunol (2003) 3(12):984–93. doi:10.1038/nri1246

7. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med (1985) 161(3):526–46. doi:10.1084/jem.161.3.526

8. Caux C, Denazot-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperation in the generation of dendritic Langerhans cells. Nature (1992) 360(6401):258–61. doi:10.1038/360258a0

9. Dubois B, Briden JM, Fayette J, Barthelemy C, Banchereau J, Caux C, et al. Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol (1999) 66(2):224–30. doi:10.1002/jlb.6602224

10. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, et al. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med (1997) 185(5):941–51. doi:10.1084/jem.185.5.941

11. Fayette J, Dubois B, Vandenbergbe S, Briden JM, Vanbervliet B, Durand I, et al. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med (1997) 185(11):1909–18. doi:10.1084/jem.185.11.1909

12. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol (1998) 161(3):1313–9.

13. Litinskiy MB, Nadell B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BlyS and APRIL. Nat Immunol (2002) 3(9):822–9. doi:10.1038/nm829

14. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 1(1):37–41. doi:10.1038/36788

15. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity (2008) 29(3):497–510. doi:10.1016/j.immuni.2008.07.013

16. Crozey S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 29:621–63. doi:10.1146/annurev-immunol-031110-104100

17. Schmitt N, Bustamante J, Bourdery L, Benteribel SE, Boisson-Dupuis S, Hamlin F, et al. IL-12 receptor beta1 deficiency alters in vivo T follicular helper cell response in humans. Blood (2013) 121(7):3757–83. doi:10.1182/blood-2012-08-448902

18. Schmitt N, Morita R, Bourdery L, Benteribel SE, Zuurawski SM, Banchereau J, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity (2009) 31(1):158–69. doi:10.1016/j.immuni.2009.04.016

19. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 19(2):225–34. doi:10.1016/S1074-7613(03)00208-5

20. Pock H, Wagner M, Battany J, Röthlin S, Henschel D, Hornung V, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood (2004) 103(8):3058–64. doi:10.1182/blood-2003-08-2972

21. Shaw I, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cell regulate B-cell growth and differentiation via CD70. Blood (2010) 115(7):3051–7. doi:10.1182/blood-2009-08-239145

22. Tange SG, Bryant VL, Cus AK, Good K. BAFF, APRIL and human B cell disorders. Semin Immunol (2006) 18(5):305–17. doi:10.1016/j.smim.2006.04.004

23. Cacac H, Yildiz U, Reizis B, Kalinke U, Johansson-Lindbohm B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity (2009) 31(3):491–501. doi:10.1016/j.immuni.2009.07.005

24. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 294(5546):1540–3. doi:10.1126/science.1064980

25. Bennett L, Palucka AK, Arce E, Cantrell V, Borvák J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 197(6):777–88. doi:10.1084/jem.20021996

26. Ding C, Cai Y, Marroquin J, Idstad ST, Yan J. Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. J Immunol (2009) 183(1):740–9. doi:10.4049/jimmunol.0901175

27. Delamarme L, Pack M, Chang H, Lennell I, Trombeta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 307(5715):1630–4. doi:10.1126/science.1108003

The cross-talk of antigen presenting cells and B cells

Xu and Banchereau

www.frontiersin.org January 2014 | Volume 4 | Article 504 | 5
by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection. Eur J Immunol (2005) 35(10):2962–9. doi:10.1002/eji.200526216

66. Xu W, Joo H, Clayton S, Dullaars M, Herve MC, Blankenship D, et al. Macrophages induce differentiation of plasma cells through CXCL10/IFN-β. J Exp Med (2012) 209(10):1813–23. doi:10.1084/jem.20112142

67. Carrasco VR, Batista FD. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J (2005) 24(5):889–99. doi:10.1038/sj.emboj.7600944

68. Nardelli B, Beveldere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood (2001) 97(1):198–204. doi:10.1182/blood.V97.1.198

69. Craxton A, Magalietti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell–dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood (2003) 101(11):4646–71. doi:10.1182/blood-2002-10-3123

70. Joo H, Coquery C, Xue Y, Gayet I, Dillon SR, Panaro M, et al. Serum from patients with SLE instructs monocytes to promote IgA and IgG plasmablast differentiation. J Exp Med (2012) 209(7):1335–48. doi:10.1087/20110132940

71. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, Hardie DL, et al. Dendritic cells and monocyte/macrophages that create the IL-6–APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol (2009) 182(4):2113–23. doi:10.4049/jimmunol.0802771

72. Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood (2011) 118(7):1838–44. doi:10.1182/blood-2011-01-32940

73. Chu VT, Frohlich A, Steinhauer G, Scheel T, Roch T, Fälatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 12(2):151–9. doi:10.1038/ni.1891

74. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol (2010) 28:185–210. doi:10.1146/annurev-immunol-030409-101216

75. Pierce SK, Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol (2010) 10(11):767–77. doi:10.1038/nri2853

76. Soares H, Waechter H, Gläschenuxbnus N, Mougeux E, Yagita H, Mizzenina O, et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-γamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 204(5):1095–106. doi:10.1087/20070716

77. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194(6):769–79. doi:10.1084/jem.194.6.769

78. Bonifaz L, Bonnay D, Mahlke K, Rivera M, Nussenzwieg MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 196(12):1627–38. doi:10.1084/jem.20021598

79. Kлечевский Е, Фламар А, Како Ѕ, Бланк И, Лу М, О’Бар А, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood (2011) 118(10):2645–50. doi:10.1182/blood-2010-07-296221

80. Meyer-Wentrup F, Cambi A, Joosten B, Looman MW, de Vries IJ, Figdor CG, et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-γamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 204(5):1095–106. doi:10.1087/20070716

81. Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol (2003) 8(5):518–25. doi:10.1189/jlb.0608352

82. Ni L, Gayet I, Zurawski S, Duluc D, Flamar AL, Li XH, et al. Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses. J Immunol (2010) 185(6):3054–13. doi:10.4049/jimmunol.1000999

83. Sancho D, Mourao-Sa D, Joffre II, Figdor CG, et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol (2003) 8(5):518–25. doi:10.1189/jlb.0608352

84. Flacher V, Sparber F, Tripp CH, Romani N, Stoitzenz T. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother (2009) 58(7):1137–47. doi:10.1007/s00262-008-0563-9

Frontiers in Immunology | B Cell Biology
85. Caminschi I, Vremec D, Ahmet F, Lahoud MH, Villadangos JA, Murphy KM, et al. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice. *Mol Immunol* (2012) 50(1-2):9–17. doi:10.1016/j.molimm.2011.11.008

86. Joffre OP, Sancho D, Zelenay S, Keller AM, Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. *Eur J Immunol* (2010) 40(5):1255–65. doi:10.1002/eji.201040419

87. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity* (2013) 39(1):38–48. doi:10.1016/j.immuni.2013.07.004

88. Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. *Proc Natl Acad Sci U S A* (2000) 97(2):847–52. doi:10.1073/pnas.97.2.847

89. White AL, Tutt AL, James S, Wilkinson KA, Castro FV, Dixon SV, et al. Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant. *Immunology* (2010) 131(1):44–51. doi:10.1111/j.1365-2567.2010.03285.x

90. Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. *Immunity* (2013) 38(4):831–44. doi:10.1016/j.immuni.2012.12.008

91. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat Med* (1996) 2(1):52–8. doi:10.1038/nm0196-52

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 24 October 2013; accepted: 20 December 2013; published online: 06 January 2014.

Citation: Xu W and Banchereau J (2014) The antigen presenting cells instruct plasma cell differentiation. *Front. Immunol.* 4:504. doi: 10.3389/fimmu.2013.00504

This article was submitted to B Cell Biology, a section of the journal *Frontiers in Immunology*. Copyright © 2014 Xu and Banchereau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.